+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

L

Actively Recruiting

Researchers are evaluating the long-term safety and effectiveness of the FDA-approved VARIPULSE catheter system for pulmonary vein isolation PVI in treating people with symptomatic paroxysmal atrial fibrillation PAF. This study focuses on participants who are candidates for catheter ablation due to symptoms and have not responded well to certain antiarrhythmic drugs. Participants will undergo electrophysiology mapping and pulsed field ablation PFA using the VARIPULSE catheter combined with the TRUPULSE generator. This treatment is designed to isolate pulmonary veins to manage atrial fibrillation symptoms. The study observes outcomes both shortly after the procedure and over the long term. During the study, participants will be monitored for early adverse events within 7 days after the ablation procedure. They will also be followed for freedom from documented atrial tachyarrhythmia episodes from about 2 months up to 3 years after treatment. Assessments include clinical evaluations and adherence to follow-up testing to understand the devices safety and effectiveness over time.

Age: 22Years +All GendersPhase Not Applicable
25 locations
E

Actively Recruiting

Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.

Age: 18Years +All GendersPhase 3
679 locations
S

Actively Recruiting

Researchers are evaluating the use of apixaban compared to aspirin to prevent stroke or death in patients who have had a recent intracerebral hemorrhage ICH and also have atrial fibrillation AF. This phase III randomized, double-blinded trial aims to determine if apixaban is superior in preventing any type of stroke or death, as well as if it leads to better functional recovery measured by the modified Rankin Scale. The study will enroll 700 patients and follow them for 12 to 36 months to assess these outcomes. Participants will be randomly assigned to receive either apixaban or aspirin. Apixaban dosing is typically 5 mg twice daily, with a reduced dose of 2.5 mg twice daily for those meeting specific criteria such as older age, lower body weight, or certain medication use. Aspirin is given once daily at a dose of 81 mg. The study includes a treatment period after recent ICH, with careful monitoring for safety and efficacy. During the study, participants will undergo regular assessments including evaluation of stroke occurrence, death, and changes in functional status using the modified Rankin Scale. Safety and adherence will be monitored throughout the follow-up period, which ranges from 12 months up to 3 years. The research team will collect data to understand the benefits and risks of apixaban versus aspirin in this patient population.

Age: 18Years +All GendersPhase 3
187 locations
L

Actively Recruiting

Researchers are studying the long-term effects of maridebart cafraglutide in adults with obesity or overweight who also have type 2 diabetes. This Phase 3 trial aims to evaluate how well the drug works, its safety, and how well participants tolerate it over time. The trial is an extension of a previous study, allowing continued assessment of the treatments impact over a longer period. Participants receive different doses of maridebart cafraglutide or placebo, administered as injections under the skin. Those who had low doses in the previous study continue with the same low dose every 4 weeks. Participants who had medium or high doses in the earlier trial may be randomly assigned to continue their dose every 4 or 8 weeks, or receive placebo injections every 4 weeks. Some participants who previously received placebo will start a high dose with a gradual increase before reaching the full dose. During the study, participants will have regular visits for up to 48 weeks to monitor body weight changes, blood sugar control, waist size, and quality of life. Researchers will carefully track any side effects or serious health events throughout the treatment. The study runs until March 2028, providing detailed information on the long-term use of maridebart cafraglutide.

Age: 18Years - 99YearsAll GendersPhase 3
45 locations
O

Actively Recruiting

This research study focuses on both adult and pediatric participants diagnosed with Chronic Granulomatous Disease CGD. The main goal is to understand how common specific antibodies and inflammatory cytokines are in people living with CGD by measuring these markers in their blood. Participants will have blood samples collected to measure levels of adenovirus-specific antibodies and inflammatory cytokines. This is an observational study, meaning no treatments are given instead, the study observes and records these blood markers to characterize their prevalence in this patient group. During the study, participants will provide blood samples for laboratory analysis of antibody titers and cytokine levels. The main outcomes measured include total adenoviral-specific antibody levels and neutralizing antibody levels, along with inflammatory cytokine concentrations. The study is expected to be completed by December 2026.

All AgesAll Genders
52 locations